Glycorex Transplantation AB (GTAB B): Results from Norwegian platelet evaluation presented at conference
As previously announced, a blood bank in Norway has evaluated our transfusion product, Glycosorb® ABO (4 ml), for the preparation of low-titer blood group O platelet concentrate with positive results. The findings were recently presented at a national transfusion conference in Norway.
Apheresis platelet concentrate from blood group O contains anti-A/B antibodies (blood group-specific antibodies) and can be transfused to recipients with blood group A, B, or AB, as long as the concentrate contains a low titer (level) of these anti-A/B antibodies. The method traditionally used to reduce anti-A/B antibodies from blood group O platelet concentrate involves treating the concentrate with centrifugation and diluting it with a buffer solution.
The conclusion from the evaluation was that Glycosorb® ABO (4 ml) was more effective in reducing anti-A/B antibodies than the current method, resulted in lower platelet activation, and that the procedure itself was easy to perform with our product.
This confirms the experience from NHS in the UK last year, where it was shown that anti-A/B antibody titers in platelet concentrate can be effectively reduced with Glycosorb® ABO (4 ml).
Platelet transfusions are primarily used in oncology, surgery, and hematology, where patients have an increased need for platelets to prevent or treat bleeding.
It is estimated that approximately 2.4 million units of platelets are used annually in Europe. Of these, about 1 million units are apheresis platelets (edqm, 2016).
For more information, please contact:
Johan Nilsson, CEO
Email: johan.nilsson@glycorex.com,Tel: +46 46 286 5230
Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.
The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 25 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. Product development and production takes place in the company's own facility in Lund, Sweden.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 7,000 transplants in over 30 countries.
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.